Germline testing checks an eligible person's DNA for genetic inherited mutations that could potentially increase the risk of developing cancers or other health problems. Researchers from Rutgers Cancer Institute of New Jersey and Dana-Farber Cancer Institute developed and evaluated a computational pipeline that utilizes information commonly provided in academic and commercial tumor sequencing assays to predict the origin of detected DNA alterations with the goal of helping clinicians in identifying germline alterations in patients. Read More